The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

Size: px
Start display at page:

Download "The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?"

Transcription

1 AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division of Preventive Medicine Brigham and Women's Hospital Principal Investigator, Boston site of the WHI Professor of Medicine and the Michael and Lee Bell Professor of Women s Health Harvard Medical School, Boston, Massachusetts Take Home Points : Menopausal hormone therapy (HT) continues to have an important clinical role in the management of menopausal symptoms. Current evidence does not support the use of HT for the prevention of cardiovascular disease or other chronic diseases. The best candidates for systemic HT tend to be recently menopausal and symptomatic women who are in generally good health, due to their low absolute risks of adverse events and greater potential for quality-of-life benefits. Risk stratification and a personalized approach to HT decision making is recommended. Summary and Tables: Menopausal hormone therapy (HT) has complex biological effects but continues to have an important clinical role in the management of vasomotor and other menopausal symptoms. Findings from the Women s Health Initiative (WHI), which led to a dramatic reduction in HT use, are summarized in Table 1 (overall study population) and stratified by by age group in Table 2. WHI and other randomized clinical trials have helped to clarify the benefits and risks of HT and provided insights to improve decision making. Several clinical characteristics have utility in identifying women for whom benefits of HT are likely to outweigh the risks. Age and time since menopause are strong predictors of health outcomes and absolute risks on HT, especially for estrogen alone. In the Women s Health Initiative trial of conjugated equine estrogens (CEE) alone, younger women (50-59 years) had more favorable results for all-cause mortality, myocardial infarction, and the global index (P values for trend by age <0.05), but not for stroke and venous thrombosis. Age trends were less clear for CEE+MPA, due to increased risks of breast cancer, stroke, and venous thrombosis in all age groups. Absolute risks of adverse events were lower in younger than older women in both trials, however. Other predictors of lower risk from HT include favorable lipid status and absence of the metabolic syndrome (Table 3). Transdermal administration may be associated with lower risks of venous thrombosis and stroke, but additional research is needed. The use of risk stratification and personalized risk assessment offers promise for improved benefit:risk profile and safety of HT. 1

2 Table 1. Benefits and risks (absolute risks per 10,000 women per yr, rate differences, and relative risks) of postmenopausal hormone therapy on chronic disease outcomes in the overall study population of women aged 50 to 79 years in the Women s Health Initiative (WHI) estrogen-progestin and estrogen-alone trials a Outcome Estrogen-progestin trial (n=16,608) Estrogen-alone trial (n=10,739) Number of cases per 10,000 women per year Number of cases per 10,000 women per year E+P Placebo Difference b RR (95% CI) b ET Placebo Difference b RR (95% CI) b Benefits (not including vasomotor sx) Hip fracture ( ) ( ) Type 2 diabetes ( ) ( ) Risks Stroke ( ) ( ) Pulmonary embolism ( ) ( ) Deep vein thrombosis ( ) ( ) Breast cancer c ( ) ( ) Gallbladder disease ( ) ( ) Neutral or uncertain risks and benefits d Coronary heart disease e ( ) ( ) Myocardial infarction ( ) ( ) Ovarian cancer ( ) Not available Colorectal cancer ( ) ( ) Dementia (age 65) ( ) ( ) Total mortality ( ) ( ) Global index d,f ( ) ( ) a. The estrogen-progestin arm of the WHI assessed 5.6 years of conjugated equine estrogen (0.625 mg/d) plus medroxyprogesterone acetate (2.5 mg/d) versus placebo. The estrogen-alone arm of the WHI assessed 7.1 years of conjugated equine estrogen (0.625 mg/d) versus placebo. b. RR, relative risk; CI, confidence interval. c. Divergent results for the two interventions. d. Also includes outcomes with divergent results for the two interventions. e. Coronary heart disease is defined as nonfatal myocardial infarction or coronary death. f. The global index is a composite outcome representing the first event for each participant from among the following: coronary heart disease, stroke, pulmonary embolism, breast cancer, colorectal cancer, endometrial cancer (estrogenprogestin trial only), hip fracture, and death. Because participants can experience more than one type of event, the global index cannot be derived by a simple summing of the component events. Source: Manson JE, Chlebowski RT, Stefanick ML, et al. JAMA 2013; 310(13):

3 Table 2. Effects of postmenopausal hormone therapy on cardiovascular outcomes in the Women s Health Initiative estrogen-progestin and estrogen-alone trials, according to age at study entry Intervention phase (5.6 years of randomized treatment) Outcome Estrogen-progestin Estrogen alone RR (95% CI) P RR (95% CI) P Coronary heart disease * y 1.34 ( ) ( ) y 1.01 ( ) 0.95 ( ) y 1.31 ( ) 1.09 ( ) Myocardial infarction y 1.32 ( ) ( ) y 1.05 ( ) 0.95 ( ) y 1.46 ( ) 1.24 ( ) Stroke y 1.51 ( ) ( ) y 1.45 ( ) 1.55 ( ) y 1.22 ( ) 1.29 ( ) Pulmonary embolism y 2.05 ( ) ( ) y 1.69 ( ) 1.72 ( ) y 2.54 ( ) 0.85 ( ) RR, relative risk; CI, confidence interval. *Coronary heart disease is defined as nonfatal myocardial infarction or coronary death. Source: Manson JE, Chlebowski RT, Stefanick ML, et al. JAMA 2013; 310(13):

4 Table 3. CHD risk in the Women s Health Initiative estrogen-progestin and estrogen-alone trials, according to baseline levels of selected markers Marker OR (95% CI) for HT treatment effect P for interaction LDL cholesterol (mg/dl) < ( ) ( ) LDL/HDL cholesterol ratio < ( ) ( ) C-reactive protein < ( ) ( ) Metabolic syndrome * No 0.97 ( ) 0.03 Yes 2.26 ( ) Waist circumference 88 cm 1.03 ( ) 0.12 >88 cm 1.93 ( ) OR, odds ratio; CI, confidence interval. * Metabolic syndrome was defined as having three or more of the following: waist size >88 cm (>80 cm for Asians and Native Americans); systolic blood pressure >130 mm/hg or diastolic blood pressure >85 mm Hg; fasting glucose >100 mg/dl; HDL cholesterol <50 mg/dl; triglycerides >150 mg/dl. Sources: Bray PF et al. Am J Cardiol 2008;101: , and Wild RA et al. Menopause 2013;20:

5 References/Suggested Readings Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:S1-S66. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310: Rossouw JE, Prentice RL, Manson JE, et al. Effects of postmenopausal hormone therapy on cardiovascular disease by age and years since menopause. JAMA 2007;297: Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and the risk of coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166: Manson JE, Bassuk SS. The menopause transition and postmenopausal hormone therapy. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jamison JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine: McGraw-Hill; Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008;168: Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289: Bray PF, Larson JC, Lacroix AZ, Manson J, Limacher MC, Rossouw JE, Lasser NL, Lawson WE, Stefanick ML, Langer RD, Margolis KL. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101: Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE. Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause 2013;20: Manson JE. The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metabolism 2013;62 Suppl 1:S Rossouw J, Bray P, Liu J, Kooperberg C, Hsia J, Lewis C, Cushman M, Bonds D, Hendrix S, Papanicolaou G, Howard T, Herrington D. Estrogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol 2011;31:

(212) 733-2324 mackay.jimeson@pfizer.com

(212) 733-2324 mackay.jimeson@pfizer.com For immediate release: July 9, 2012 Media Contacts: MacKay Jimeson (212) 733-2324 mackay.jimeson@pfizer.com Pfizer Recognizes 10 th Anniversary Of The Women s Health Initiative: A Modern Day Perspective

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18

More information

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE 40 yo woman, BMI 36. Motivated to begin diet therapy. Which of the following is contraindicated: Robert B. Baron MD MS Professor and

More information

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.

A list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke

More information

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D.

Hormone Replacement Therapy : The New Debate. Susan T. Hingle, M.D. Hormone Replacement Therapy : The New Debate Susan T. Hingle, M.D. Background Hormone replacement therapy (HRT) is extensively used in the United States, especially for: *treatment of menopausal symptoms

More information

The VITamin D and OmegA-3 TriaL (VITAL)

The VITamin D and OmegA-3 TriaL (VITAL) The VITamin D and OmegA-3 TriaL (VITAL) JoAnn E. Manson, MD, DrPH Principal Investigator, VITAL Brigham and Women's Hospital Professor of Medicine and the Michael and Lee Bell Professor of Women s Health

More information

Case Study 11: Hormone Replacement Therapy

Case Study 11: Hormone Replacement Therapy Case Study 11: Hormone Replacement Therapy October 2000 Scenario Ann McDonnald is a successful 55 year old business executive She starts her first consult with you by saying I m getting hot flushes It

More information

Obesity and the Menopause. Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology

Obesity and the Menopause. Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology Obesity and the Menopause Vanessa M. Barnabei, MD, PhD Professor and Chair Department of Obstetrics and Gynecology Educational Objectives Review normal menopausal transition Review health risks of obesity

More information

February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS

February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS February 1, 2014 RESTORING STRENGTH AND VITALITY THROUGH HORMONES FACTS, FANTASIES, POSSIBILITIES, AND PITFALLS Calvin Hirsch, MD Professor of Clinical Internal Medicine (Geriatrics) UC Davis School of

More information

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis

Psoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic

More information

Outline Introduction Oidti Oxidative damage Antioxidants properties Antioxidants and antiaging interventions Hormonal therapy Benefits of DHEA, testos

Outline Introduction Oidti Oxidative damage Antioxidants properties Antioxidants and antiaging interventions Hormonal therapy Benefits of DHEA, testos Anti-Aging Aging g Medications What is the Evidence? Sixth Annual Family Medicine Conference Crown Plaza November 11, 2007 Presented by : Jad J. Sakr, Pharm.D. Outline Introduction Oidti Oxidative damage

More information

February 25, 2014. Dear Dr. Hamburg:

February 25, 2014. Dear Dr. Hamburg: February 25, 2014 Margaret A. Hamburg, M.D. Commissioner Food and Drug Administration Department of Health and Human Services WO 2200 10903 New Hampshire Avenue Silver Spring, MD 20993-0002 Division of

More information

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study DOI 10.1007/s00198-012-2224-2 ORIGINAL ARTICLE Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study R. L. Prentice & M. B. Pettinger

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

The menopausal transition usually has three parts:

The menopausal transition usually has three parts: The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of

More information

PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie

PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES. Richard L. Tannen, M.D., Mark Weiner, Dawei Xie PROMISE & PITFALLS OF OUTCOMES RESEARCH USING EMR DATABASES Richard L. Tannen, M.D., Mark Weiner, Dawei Xie GOALS OF STUDY Determine Whether Studies Using EMR Database Yield Valid Outcome Assessment Major

More information

Neal Rouzier responds to the JAMA article on Men and Testosterone

Neal Rouzier responds to the JAMA article on Men and Testosterone Neal Rouzier responds to the JAMA article on Men and Testosterone On the first day the JAMA article was released I received 500 emails from physicians and patients requesting my opinion of the article

More information

Case studies of bias in real life epidemiologic studies. Bias File 1. The Rise and Fall of Hormone Replacement Therapy

Case studies of bias in real life epidemiologic studies. Bias File 1. The Rise and Fall of Hormone Replacement Therapy Case studies of bias in real life epidemiologic studies Bias File 1. The Rise and Fall of Hormone Replacement Therapy Compiled by Madhukar Pai, MD, PhD Jay S Kaufman, PhD Department of Epidemiology, Biostatistics

More information

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke

More information

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität

More information

Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease

Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or a basis for reimbursement and coverage policies. AHRQ

More information

ABSTRACT. Home Current Issue All Issues Online First Specialties & Topics CME Multimedia Quizzes For Authors Subscribe

ABSTRACT. Home Current Issue All Issues Online First Specialties & Topics CME Multimedia Quizzes For Authors Subscribe SIGN IN (Create a Free Personal Account) Journals > Specialties & Topics Store Physician Jobs About Mobile Search The JAMA Network Search JAMA Advanced Search Home Current Issue All Issues Online First

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Menopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015

Menopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015 PRIMARY CARE WOMEN S HEALTH FORUM GUIDELINES Menopause Guidance on management and prescribing HRT for GPs based on NICE guidance 2015 Written by Dr Imogen Shaw This guidance is designed to support you

More information

Hormone replacement therapy:

Hormone replacement therapy: www.bpac.org.nz keyword: hrt Hormone replacement therapy: latest evidence and treatment recommendations Key advisor: Dr Helen Roberts, Senior Lecturer, Department of Obstetrics and Gynaecology, Faculty

More information

Coronary heart disease in menopausal women: Implications of primary and secondary prevention trials of hormones

Coronary heart disease in menopausal women: Implications of primary and secondary prevention trials of hormones Maturitas 51 (2005) 51 63 Coronary heart disease in menopausal women: Implications of primary and secondary prevention trials of hormones Jacques E. Rossouw National Heart, Lung, and Blood Institute, National

More information

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,

More information

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center

More information

Randomized, double-blind, parallel-group, multicenter, doubledummy

Randomized, double-blind, parallel-group, multicenter, doubledummy ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)

More information

Technology Assessment

Technology Assessment Technology Assessment Lifestyle Interventions for Four Conditions: Type 2 Diabetes, Metabolic Syndrome, Breast Cancer, and Prostate Cancer Technology Assessment Program Prepared for: Agency for Healthcare

More information

Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?

Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

Aging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone

Aging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent

More information

Insulin Resistance and PCOS: A not uncommon reproductive disorder

Insulin Resistance and PCOS: A not uncommon reproductive disorder Insulin Resistance and PCOS: A not uncommon reproductive disorder Joyce L. Ross, MSN, CRNP, CS, FNLA, FPCNA Diplomate Accrediation Council for Clinical Lipidology President Preventive Cardiovascular Nurses

More information

Appendix: Description of the DIETRON model

Appendix: Description of the DIETRON model Appendix: Description of the DIETRON model Much of the description of the DIETRON model that appears in this appendix is taken from an earlier publication outlining the development of the model (Scarborough

More information

MY TYPE 2 DIABETES NUMBERS

MY TYPE 2 DIABETES NUMBERS BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,

More information

BREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1

BREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh

More information

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant

More information

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS

More information

Is hypoglycemia an issue in type 2 diabetes?

Is hypoglycemia an issue in type 2 diabetes? King s Diabetes Research Group Is hypoglycemia an issue in type 2 diabetes? Stephanie A Amiel RD Lawrence Professor of Diabetic Medicine King s College London Conflicts of interest None! (Currently working

More information

Postmenopausal hormone replacement therapy (HRT)

Postmenopausal hormone replacement therapy (HRT) Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Linda L. Humphrey, MD, MPH; Benjamin K.S. Chan, MS; and Harold C. Sox, MD Purpose: To evaluate the value

More information

25-hydroxyvitamin D: from bone and mineral to general health marker

25-hydroxyvitamin D: from bone and mineral to general health marker DIABETES 25 OH Vitamin D TOTAL Assay 25-hydroxyvitamin D: from bone and mineral to general health marker FOR OUTSIDE THE US AND CANADA ONLY Vitamin D Receptors Brain Heart Breast Colon Pancreas Prostate

More information

Florida Breast Health Specialists Breast Cancer Information and Facts

Florida Breast Health Specialists Breast Cancer Information and Facts Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to

More information

Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer

Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer Linköping University Medical Dissertations No. 1430 Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer Johan Rosell Linköping University, Faculty of Health Sciences

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men

Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men G. Engström, MD, PhD; P. Lind, MD; B. Hedblad, MD, PhD; L. Stavenow, MD, PhD; L.

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Absolute cardiovascular disease risk assessment

Absolute cardiovascular disease risk assessment Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke

Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.

More information

Use of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence?

Use of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence? CPD Paper 5 605 Use of Hormone Replacement Therapy in the Asymptomatic Postmenopausal Woman: What is the Current Evidence? F H Loh,*FAMS, MRCOG (Lond), M Med (O & G) Abstract The publication of the Women

More information

POSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY

POSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY POSTMENOPAUSAL ESTROGEN REPLACEMENT THERAPY Dorie W. Schwertz, PhD (2/01) University of Illinois at Chicago Hormone Replacement Therapy (HRT) and Estrogen Replacement Therapy (ERT) Menopause - loss of

More information

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:

More information

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Mortality Assessment Technology: A New Tool for Life Insurance Underwriting Guizhou Hu, MD, PhD BioSignia, Inc, Durham, North Carolina Abstract The ability to more accurately predict chronic disease morbidity

More information

I. Background. II. Eligibility Geographic Scope: United States Only International(specify country/countries) Applicant Eligibility Criteria:

I. Background. II. Eligibility Geographic Scope: United States Only International(specify country/countries) Applicant Eligibility Criteria: Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Enabling effective conversations regarding menopausal vasomotor symptoms and other conditions associated with menopause utilizing

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 13 October 2005 Doc. Ref. EMEA/CHMP/021/97 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

PROVERA (medroxyprogesterone acetate) Product Monograph Page 34 of 38

PROVERA (medroxyprogesterone acetate) Product Monograph Page 34 of 38 PART III: CONSUMER INFORMATION PR PROVERA* (medroxyprogesterone acetate) This leaflet is part III of a three-part "Product Monograph" published when PROVERA was approved for sale in Canada and is designed

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Improving cardiometabolic health in Major Mental Illness

Improving cardiometabolic health in Major Mental Illness Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic

More information

Red Alert for Women s Hearts Women and Cardiovascular Research in Europe

Red Alert for Women s Hearts Women and Cardiovascular Research in Europe Red Alert for Women s Hearts Women and Cardiovascular Research in Europe November 2009 Red Alert on Women s Hearts Women and Cardiovascular Research in Europe November 2009 European Heart Health Strategy

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

Karen Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc.

Karen Kovach M.S, R.D Chief Scientific Officer Weight Watchers International Inc. Waking up to real solutions to Chronic Disease: Tackling obesity can reduce the burden of chronic disease and deliver substantial cost savings to struggling European healthcare systems Karen Kovach M.S,

More information

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One

More information

Dietary Composition for Weight Loss and Weight Loss Maintenance

Dietary Composition for Weight Loss and Weight Loss Maintenance Dietary Composition for Weight Loss and Weight Loss Maintenance Bridget M. Hron, MD Instructor in Pediatrics, Harvard Medical School Staff Physician in Gastroenterology & Nutrition and New Balance Foundation

More information

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works?

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? DAVID P. GOWMAN, D.O. S E C T I O N CHIEF, CARDIOLOGY P R O G R A M D I R E C T O R, CARDIOLOGY F E L L O W S H I P B

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

Coronary Heart Disease (CHD) Brief

Coronary Heart Disease (CHD) Brief Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs

More information

What is an Evidence-Based, Value-Based Health Care System? (Part 1)

What is an Evidence-Based, Value-Based Health Care System? (Part 1) Evidence-Based Medicine What is an Evidence-Based, Value-Based Health Care System? (Part 1) By Sheri Strite and Michael E. Stuart, MD IN THIS ARTICLE The two biggest issues facing health care organizations

More information

DRAFT COPY: PERSONAL USE ONLY

DRAFT COPY: PERSONAL USE ONLY Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 positions statements on peri- and postmenopausal hormone replacement therapy Skouby S.O. Al-Azzawi F. Barlow D. Calaf-Alsina

More information

Promoting the Fountain of Youth: Low-T and Estrogen Deficiency

Promoting the Fountain of Youth: Low-T and Estrogen Deficiency Promoting the Fountain of Youth: Low-T and Estrogen Deficiency Adriane Fugh-Berman MD Georgetown University Medical Center ajf29@georgetown.edu Hormone Therapy in Women Animal glandulars became popular

More information

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64

Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

Albumin and All-Cause Mortality Risk in Insurance Applicants

Albumin and All-Cause Mortality Risk in Insurance Applicants Copyright E 2010 Journal of Insurance Medicine J Insur Med 2010;42:11 17 MORTALITY Albumin and All-Cause Mortality Risk in Insurance Applicants Michael Fulks, MD; Robert L. Stout, PhD; Vera F. Dolan, MSPH

More information

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions

Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions Hormone Restoration: Is It Right for You? Patricia A. Stafford, M.D. Founder, Wellness ReSolutions IMPORTANCE OF HORMONE BALANCE Importance of Hormone Balance Help you live a long, healthy life Help you

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?

More information

Androgens and CVD. Brandon Orr- Walker April 2014

Androgens and CVD. Brandon Orr- Walker April 2014 Androgens and CVD Brandon Orr- Walker April 2014 Agenda What is normal physiology of Aging? Hypogonadism and disease If some is good is more becer? CVD safety Clinical features of Androgen Deficiency

More information

DIETARY ISSUES IN DIABETES

DIETARY ISSUES IN DIABETES DIETARY ISSUES IN DIABETES Elizabeth J Mayer Davis, PhD Department of Nutrition, Gillings School of Global Public Health Department of Medicine, School of Medicine University of North Carolina at Chapel

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Testosterone Treatment in Older Men

Testosterone Treatment in Older Men Testosterone Treatment in Older Men J. Bruce Redmon, M.D. Professor Division of Endocrinology Departments of Medicine and Urologic Surgery Disclosure Information I have no financial relationships to disclose.

More information

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell

More information

African Americans & Cardiovascular Diseases

African Americans & Cardiovascular Diseases Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age

More information

Secure Messaging Evidence Table

Secure Messaging Evidence Table APPENDIX E. Evidence Tables Secure Messaging Evidence Table Health Outcomes Simon, 2011 9 RCT; N=208 patients; 04/09-10/09 Elkjaer, 2010 1 Zhou, 2010 2 Harris, 2009 3 Ralston, 2009 6 Tuil, 2007 4 RCT;

More information

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease. March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding

More information

Do You Know the Health Risks of Being Overweight?

Do You Know the Health Risks of Being Overweight? Do You Know the Health Risks of Being Overweight? U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH WIN Weight-control Information Network What are the risks to my health from

More information

The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005

The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005 The South Asian Indian Women s s Weight Loss Study Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005 South Asian Emigrants and second generation from India Bhutan Bangladesh Maldives Nepal Pakistan

More information

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost

Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler

More information

PDL Class: Topical Androgens

PDL Class: Topical Androgens Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Topical Androgens Month/Year of Review:

More information

Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome

Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual

More information